P&G’s $3.8 Billion Thorne Acquisition Advances, Aiming for Fiscal 2027 Close

Procter & Gamble (NYSE: PG) has confirmed that its previously announced plan to acquire wellness and supplement brand Thorne for $3.8 billion remains on track, with the transaction expected to close in its fiscal year 2027, contingent upon regulatory approval and customary closing conditions. The acquisition agreement was signed on August 4, 2026, and there have been no subsequent material updates indicating delays or revisions to the timeline.

Acquisition Timeline and Financial Details

The acquisition deal, publicly revealed on August 4, 2026, involves Procter & Gamble expanding its Health Care portfolio by adding Thorne, a science-focused wellness company known for high-quality supplements and personalized health solutions through practitioner partnerships. The agreement remains subject to regulatory approvals and other closing conditions. The closing is anticipated during fiscal year 2027. (Note: P&G’s fiscal year ends on June 30.)

These details are corroborated by P&G’s August 4 announcement and reiterated in its recently filed 2026 annual report. (Annual report published last month.)

Strategic Rationale and Investor Implications

The acquisition aligns with Procter & Gamble’s strategy to bolster its presence in the growing self-care and personalized wellness segments—especially in areas driven by science-backed products and practitioner credibility. With consumers increasingly prioritizing preventive health and personalized wellness, the addition of Thorne positions P&G as a stronger contender in that fast-developing space.

Next Steps and Monitoring Points

Investors should monitor regulatory developments closely. Any delays in approvals could impact the timing of the closing. P&G and Thorne must satisfy antitrust and other regulatory requirements before completion of the deal.

In addition, keeping an eye on integration developments post-close will be important, particularly regarding how P&G plans to scale Thorne’s product offerings across its distribution channels and whether any cost synergies or branding changes emerge.

Significance for P&G Stock

While no immediate stock reaction can be firmly attributed to the acquisition, the strategic move underscores P&G’s emphasis on health and wellness as key growth drivers. With the current share price at approximately $144.91 (as of October 2), investors are watching for how the deal might contribute to long-term growth and margin improvement.

Procter & Gamble confirmed its intention to acquire Thorne for $3.8 billion, with completion expected during fiscal year 2027, pending regulatory approval and customary closing conditions.

As the company works toward closing this deal, its success in integrating Thorne’s brand and expanding its reach in personalized health care will be critical to watch in assessing P&G’s trajectory in the increasingly competitive wellness market.